Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcifications

Not Applicable

Not yet recruiting

• Conditions: Liver Cirrhosis

• Registration Number: NCT07201649
• Lead Sponsor: Centre Hospitalier Universitaire de Nice

Brief Summary

Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-09
• Study First Submitted: 2025-09-22
• Study First Submitted QC: 2025-09-30
• Last Update Submitted: 2025-09-30
• Study First Posted: 2025-10-01
• Last Update Posted: 2025-10-01
• Study Start: 2025-10-30
• Primary Completion: 2028-10-30
• Study Completion: 2029-10-30

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 95

Inclusion Criteria

• everyone requiring liver transplantation for the treatment of a chronic liver disease

Exclusion Criteria

• MELD score >25, viral replication

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
hepatic transplantation reduces arterial calcification	On the 7th day after surgery	compare the percent of patients with AC progression before and after liver tranplantation

Secondary Outcome Measures

Name	Time	Method
increase of PPi plasma level after liver transplantation	at inclusion and at 3 months	comparison of mean plasma levels before and after
identify arterial calcification related factors	On the 7th day after surgery	separation of patients according to AC progression (yes or no) and machine learning analysis with all relevant factors

Trial Locations

Locations (1)

CHU de Nice; 🇫🇷 Nice, Alpes-maritimes, France